Literature DB >> 34981295

Monoallelic MUTYH pathogenic variants ascertained via multi-gene hereditary cancer panels are not associated with colorectal, endometrial, or breast cancer.

Amanda Bartenbaker Thompson1, Erin G Sutcliffe2, Kevin Arvai2,3, Maegan E Roberts2, Lisa R Susswein2, Megan L Marshall2, Rebecca Torene2, Kristen J Vogel Postula4, Kathleen S Hruska2, Shaochun Bai2.   

Abstract

We aimed to determine whether monoallelic MUTYH pathogenic and likely pathogenic variants (PVs) are associated with colorectal, breast, and endometrial cancer. Cases were individuals with colorectal, female breast, or endometrial cancer who reported European ancestry alone and underwent a multi-gene hereditary cancer panel at a large reference laboratory. Controls were individuals of European (non-Finnish) descent from GnomAD with cancer cohorts removed. We performed a Fisher's exact test to generate odds ratios (ORs) with 95% confidence intervals (CI). Prevalence of single MUTYH PVs in cancer cohorts versus controls, respectively, was: colorectal cancer, 2.1% vs. 1.8% (OR 1.2, 95% CI 0.99-1.5, p = 0.064); breast cancer 1.9% vs. 1.7% (OR 1.1, 95% CI 0.96-1.3, p = 0.15); and endometrial cancer, 1.7% vs. 1.7% (OR 0.98; 95% CI 0.70-1.3, p = 0.94). Using the largest colorectal and endometrial cancer cohorts and one of the largest breast cancer cohorts from a single case-control study, we did not observe a significant difference in the prevalence of monoallelic MUTYH PVs in these cohorts compared to controls. Additionally, frequencies among cancer cohorts were consistent with the published MUTYH carrier frequency of 1-2%. These findings suggest there is no association between colorectal, endometrial, or breast cancer and MUTYH heterozygosity in individuals of European ancestry.
© 2021. The Author(s), under exclusive licence to Springer Nature B.V.

Entities:  

Keywords:  Breast neoplasms; Colorectal neoplasms; Endometrial neoplams; Genetic testing; Hereditary; Heterozygote; Neoplastic syndromes; mutY adenine glycosylase

Year:  2022        PMID: 34981295     DOI: 10.1007/s10689-021-00285-7

Source DB:  PubMed          Journal:  Fam Cancer        ISSN: 1389-9600            Impact factor:   2.375


  36 in total

1.  Cancer risks for monoallelic MUTYH mutation carriers with a family history of colorectal cancer.

Authors:  Aung Ko Win; Sean P Cleary; James G Dowty; John A Baron; Joanne P Young; Daniel D Buchanan; Melissa C Southey; Terrilea Burnett; Patrick S Parfrey; Roger C Green; Loïc Le Marchand; Polly A Newcomb; Robert W Haile; Noralane M Lindor; John L Hopper; Steven Gallinger; Mark A Jenkins
Journal:  Int J Cancer       Date:  2011-04-08       Impact factor: 7.396

2.  MutYH mutation carriers have increased breast cancer risk.

Authors:  Gad Rennert; Flavio Lejbkowicz; Ilana Cohen; Mila Pinchev; Hedy S Rennert; Ofra Barnett-Griness
Journal:  Cancer       Date:  2011-09-22       Impact factor: 6.860

3.  Mutation analysis of MUTYH in Japanese colorectal adenomatous polyposis patients.

Authors:  Keiko Taki; Yuri Sato; Sachio Nomura; Yuumi Ashihara; Mizuho Kita; Ikufumi Tajima; Kokichi Sugano; Masami Arai
Journal:  Fam Cancer       Date:  2016-04       Impact factor: 2.375

4.  Association of monoallelic MUTYH mutation among Egyptian patients with colorectal cancer.

Authors:  Afaf Elsaid; Rami Elshazli; Fatma El-Tarapely; Hossam Darwish; Camelia Abdel-Malak
Journal:  Fam Cancer       Date:  2017-01       Impact factor: 2.375

5.  Increased risk for colorectal adenomas and cancer in mono-allelic MUTYH mutation carriers: results from a cohort of North-African Jews.

Authors:  Guy Rosner; Dani Bercovich; Yael Etzion Daniel; Hana Strul; Naomi Fliss-Isakov; Meirav Ben-Yehoiada; Erwin Santo; Zamir Halpern; Revital Kariv
Journal:  Fam Cancer       Date:  2015-09       Impact factor: 2.375

6.  Increased MUTYH mutation frequency among Dutch families with breast cancer and colorectal cancer.

Authors:  Marijke Wasielewski; Astrid A Out; Joyce Vermeulen; Maartje Nielsen; Ans van den Ouweland; Carli M J Tops; Juul T Wijnen; Hans F A Vasen; Marjan M Weiss; Jan G M Klijn; Peter Devilee; Frederik J Hes; Mieke Schutte
Journal:  Breast Cancer Res Treat       Date:  2010-02-27       Impact factor: 4.872

7.  Clinical implications of the colorectal cancer risk associated with MUTYH mutation.

Authors:  Steven J Lubbe; Maria Chiara Di Bernardo; Ian P Chandler; Richard S Houlston
Journal:  J Clin Oncol       Date:  2009-07-20       Impact factor: 44.544

8.  A MUTYH germline mutation is associated with small intestinal neuroendocrine tumors.

Authors:  Jan P Dumanski; Chiara Rasi; Peyman Björklund; Hanna Davies; Abir S Ali; Malin Grönberg; Staffan Welin; Halfdan Sorbye; Henning Grønbæk; Janet L Cunningham; Lars A Forsberg; Lars Lind; Erik Ingelsson; Peter Stålberg; Per Hellman; Eva Tiensuu Janson
Journal:  Endocr Relat Cancer       Date:  2017-06-20       Impact factor: 5.678

9.  Risk of extracolonic cancers for people with biallelic and monoallelic mutations in MUTYH.

Authors:  Aung Ko Win; Jeanette C Reece; James G Dowty; Daniel D Buchanan; Mark Clendenning; Christophe Rosty; Melissa C Southey; Joanne P Young; Sean P Cleary; Hyeja Kim; Michelle Cotterchio; Finlay A Macrae; Katherine M Tucker; John A Baron; Terrilea Burnett; Loïc Le Marchand; Graham Casey; Robert W Haile; Polly A Newcomb; Stephen N Thibodeau; John L Hopper; Steven Gallinger; Ingrid M Winship; Noralane M Lindor; Mark A Jenkins
Journal:  Int J Cancer       Date:  2016-06-02       Impact factor: 7.316

10.  Genetic variants in MUTYH are not associated with endometrial cancer risk.

Authors:  Katie A Ashton; Anthony Proietto; Geoffrey Otton; Ian Symonds; Rodney J Scott
Journal:  Hered Cancer Clin Pract       Date:  2009-01-26       Impact factor: 2.857

View more
  1 in total

1.  A Previously Unrecognized Molecular Landscape of Lynch Syndrome in the Mexican Population.

Authors:  Alejandra Padua-Bracho; José A Velázquez-Aragón; Verónica Fragoso-Ontiveros; Paulina María Nuñez-Martínez; María de la Luz Mejía Aguayo; Yuliana Sánchez-Contreras; Miguel Angel Ramirez-Otero; Marcela Angélica De la Fuente-Hernández; Silvia Vidal-Millán; Talia Wegman-Ostrosky; Abraham Pedroza-Torres; Cristian Arriaga-Canon; Luis A Herrera-Montalvo; Rosa Maria Alvarez-Gómez
Journal:  Int J Mol Sci       Date:  2022-09-30       Impact factor: 6.208

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.